Work

Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis

Year: 2013

Type: article

Study design: Observational Study

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2013.12.002

Authors: Daniel J. DeAngelo, Lei Chen, Annie Guerin, Amy Styles, Philippe Giguere-Duval, Eric Q. Wu

Institution: Dana-Farber Cancer Institute

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis Pharmaceuticals Corporation

OpenAlex ID: W1992974800

FWCI: 0.639

Cites: 17

Cited by: 5

Related to: 10